Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Plasmacytoma 1Paraproteinemias 1Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

fludarabine phosphate 2Filgrastim 2fludarabine 1filanesib 1carfilzomib 1Whole-Body Irradiation 1Steroids 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Melphalan 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Dexamethasone 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Plasma Cell × Injections, Subcutaneous × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡